New AI features have been developed by years of experience from over 50 000 patient cases and users input.
Dermicus AI Focus is a new AI feature for image quality assurance in Dermicus mobile application for checking that photos are focused and high quality. This feature supports the consultant for a high-quality remote diagnosis and prevent patients needing revisit GP for the photos to be retaken.
For example, the photo is blurred, and the user is prompted to retake the photo.
“Blurred photos being sent to the consultant, who would be unable to make a remote diagnosis, resulting in the patient returning to the GP for the photo to be retaken, is a common problem in healthcare.”
Daniel Eliasson, COO Gnosco
Dermicus AI Light is a new AI feature for image quality assurance in the Dermicus mobile application that verifies that photos are taken in the correct order, and with both polarized and non-polarized light. This is important when reviewing images to make a remote diagnosis and for historical images comparison during follow up consultation.
For example, the user has already taken a picture with polarized light and is trying to take another. The application senses that this picture has already been taken, and the user is prompted to take a picture even with non-polarized light.
Thanks to a close collaboration with our customers and academia, functionalities in the platform have developed and expanded, including new AI features for image quality assurance.
Artificial intelligence is a priority area, and we work collaboratively with leading dermatologists on innovative research projects. Gnosco continues to invest in AI and develop partnerships for research and innovation.
“Artificial intelligence is a priority area, and we work collaboratively with leading dermatologists on innovative research projects. A current example is our collaboration with dermatology consultants, to evaluate AI functionality in clinical practice, including AI applying different filters to images and how that will support the consultants’ diagnosis.”
Daniel Eliasson, COO Gnosco
